MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
OTCMQB
0.945
+0.025
+2.72%
Closed 13:59 06/25 EDT
OPEN
0.990
PREV CLOSE
0.920
HIGH
0.990
LOW
0.945
VOLUME
8.49K
TURNOVER
8.26K
52 WEEK HIGH
1.320
52 WEEK LOW
0.465
MARKET CAP
10.43M
P/E (TTM)
-1.0041
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCLI last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at BCLI last week (0608-0612)?
Weekly Report · 06/15 09:37
Weekly Report: what happened at BCLI last week (0601-0605)?
Weekly Report · 06/08 09:35
Brainstorm Cell Therapeutics director Peter J. Pitts files initial beneficial ownership statement
PUBT · 06/03 21:38
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
PR Newswire · 06/02 13:00
Weekly Report: what happened at BCLI last week (0525-0529)?
Weekly Report · 06/01 09:37
BrainStorm Adds Former FDA Leader to Board
TipRanks · 05/28 21:16
Lunai Bioworks and BrainStorm launch foundation for neurological diseases
TipRanks · 05/28 14:26
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including OTCMQB: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.